Trials / Completed
CompletedNCT01271972
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) administered IV every 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nesvacumab (REGN910/ SAR307746) |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2014-09-01
- Completion
- 2015-05-01
- First posted
- 2011-01-07
- Last updated
- 2015-06-16
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01271972. Inclusion in this directory is not an endorsement.